All Type of News
Generic substitution should be encouraged: National Health Insurance Corp.
The government fully appreciates the role which generic medicines play in the provision of comprehensive healthcare to today’s patients and accepts that making the full range of new medicines available to patients, po...
NPS opposes Dong-A’s spin-off plan
The National Pension Service (NPS), said Thursday that it opposes Dong-A Pharmaceutical’s plan to transform into a holding company, arguing it would only benefit the controlling family and undermine the interests of o...
Han named legal counsel of Gilead Sciences KoreaHan Man-hee, former director of Janssen Korea and Dong-A Pharmaceutical, was named as a legal counsel as of Jan. 21, Gilead Sciences Korea said.
She will be responsible for o...
|
Drugmakers calls for increasing R&D budget to 1 trillion won
Representatives from the Korea Pharmaceutical Manufacturers Association, the Korea Drug Research Association and the Korea Research-based Pharmaceutical Industry Association are calling for the government to support t...
12 Korean drugmakers at risk of losing “innovative drug firm’ status
The government selected 43 companies last June as “innovative pharmaceutical firms.” Those in the category receive various benefits, including priority to participate in state-run research and development projects, ta...
3 drugmakers hit for kickbacks
The Korea Food and Drug Administration (KFDA) has banned three pharmaceutical companies from selling some of their products for 30 days for offering kickbacks to doctors and hospital officials.
The Korea drug regul...
Dong-A’s spin-off plan stirs controversy
Dong-A Pharma is grappling with controversy over corporate governance as it plans to set up a holding company and put its cash cow energy drink business, Bacchus, under an unlisted firm.
The case is drawing more at...
MSD Korea begins recall of HDL cholesterol drugMSD Korea, the Korean unit of Merck & Co, said Wedneday it is recalling Tredaptive, its medicine to raise "good" HDL cholesterol levels.
The recalled five products are S3727 ...
|
Pfizer Korea to cut labor for restructuring
Pfizer Korea is undertaking large-scale restructuring in an effort to cope with the government’s decision to slash drug prices.
The company said that it will soon accept applications from 80 employees including mid...
Government to defer new drug pricing reform
The government decided to delay the new drug pricing plan to provide cash rewards to doctors and pharmacists who refuse to take rebates and instead purchase medicines at lower prices, until Feb. 1, 2014.
At the Cab...
